News | December 10, 2023
Pfizer presents marstacimab Phase 3 Data at ASH 2023
Demonstrate significant bleed reduction in hemophilia A and B
Demonstrate significant bleed reduction in hemophilia A and B
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Azelis will be the exclusive distributor for inulin, oligofructose, scFOS, texturized wheat proteins, faba beans, Beta-glucans, meatless solution
Phase 3 data expected in the second half of 2024
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
In March 2023, Japan’s Ministry of Health and Labor Welfare approved Novo Nordisk’s once-weekly subcutaneous glucagon-like peptide-1
Marks the World Head & Neck Cancer Day at the OCTF Conference
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)